Clinical trials: Inhibition
Atherosclerosis
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
This is a Phase II (proof-of-activity), double-blind, placebo-controlled, randomized, multicenter study of MLDL1278A (also known as BI-204) involving patients on standard-of-care therapy for atherosclerotic cardiovascular disease…
- Trial name
- NCT01258907
- Testing
- MLDL1278A, statin, stable dose
- Where
- 24 sites in United States, Canada
- Volunteers
- 147 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
This 3 arm study assessed the efficacy of rituximab (MabThera®/Rituxan®) in the prevention of progression of structural joint damage in participants with active rheumatoid arthritis who had an inadequate clinical response to…
- Trial name
- SCORE (NCT00578305)
- Testing
- Rituximab, Methylprednisolone, Methotrexate
- Where
- 60 sites in Argentina, Brazil and 17 more
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
Pharmacokinetics, Inhibition Enzyme
Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1
The purpose of the study is: to determine absolute bioavailability, input rates, distribution volume, renal and intestinal excretion of trospium in subjects with wild-type of SLC22A1 rs72552763 and rs12208357 and in subjects with…
- Conditions
- Pharmacokinetics, Inhibition Enzyme, Drug Interaction Potentiation
- Trial name
- NCT03011463
- Testing
- intravenous infusion of 2 mg trospium chloride, oral administration of 30 mg trospium chloride, oral administration of 300 mg ranitidine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dr. R. Pfleger Chemische Fabrik GmbH
Hepatocellular Carcinoma
A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
The purpose of this study is to determine the superiority of inhibitory effects and safety of Menatetrenone (E0167) on recurrence in patients with hepatocellular carcinoma.
- Trial name
- NCT00165633
- Testing
- Menatetrenone
- Where
- 30 sites in Japan
- Volunteers
- 540 people
- Sponsor
- Eisai Limited
Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT02917993
- Testing
- Itacitinib, Osimertinib
- Where
- 31 sites in United States, South Korea and 2 more
- Volunteers
- 59 people
- Sponsor
- Incyte Corporation
Solid Tumors, Multiple Myeloma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT02110563
- Testing
- DCR-MYC
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Atopic Dermatitis Eczema
Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
This was a Phase 3, 4-week, double-blind study to assess the safety and efficacy of ARQ-151 cream compared to vehicle cream applied once daily (qd) for 4 weeks in children 2 to 5 years of age with atopic dermatitis (AD).
- Trial name
- NCT04845620
- Testing
- Roflumilast Cream 0.05%, Vehicle Cream
- Where
- 76 sites in United States, Canada
- Volunteers
- 652 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
Atopic Dermatitis Eczema
Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
This study was a Phase 3, multicenter, open-label extension study of the long-term safety of roflumilast cream 0.15% (completers of studies ARQ-151-311 or ARQ-151-312 aged ≥6 years and ARQ-151-315 rollovers who turned 6 years of…
- Trial name
- INTEGUMENT-OLE (NCT04804605)
- Testing
- ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%
- Where
- 92 sites in United States, Canada
- Volunteers
- 1,220 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Severe Sepsis, Septic Shock
Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
The trial enrolls patients with early severe sepsis or septic shock displaying at least one newly developed organ dysfunction and showing clinical evidence of pulmonary or abdominal infection.
- Trial name
- SCIENS (NCT02246595)
- Testing
- CaCP29
- Where
- 11 sites in Germany
- Volunteers
- 72 people
- Sponsor
- InflaRx GmbH
Active Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.
- Trial name
- NCT07409103
- Testing
- ELV001 25 mg, ELV001 75 mg, ELV001 125 mg
- Where
- 34 sites in United States, Serbia and 1 more
- Volunteers
- 180 people
- Sponsor
- Elevara Medicines Limited
Advanced Solid Tumors
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose…
- Trial name
- NCT02122770
- Testing
- MLN4924, Fluconazole, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Immune System Disorder, Healthy Volunteers
A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects
The purpose of this study is to evaluate safety and pharmacokinetics (PK) effect of belumosudil on the uridine diphosphate glucuronosyltransferase (UGT)1A1 (Part 1), P glycoprotein (P-gp) (Part 2) and breast cancer resistance…
- Trial name
- NCT05806567
- Testing
- Belumosudil, UGT1A1 victim drug, P-gp victim drug
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company
Hemophilia
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to <12 years) who have severe hemophilia A or…
- Trial name
- ATLAS-KIDS (NCT07285460)
- Testing
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 37 sites in United States, Belgium and 10 more
- Volunteers
- 85 people
- Sponsor
- Sanofi
Healthy Volunteers
Single-dose and Multiple-dose X842 Phase 1 Study
The purpose of this study is to evaluate the safety and tolerability of X842 after administration of single and multiple doses in healthy subjects
- Trial name
- NCT04293965
- Testing
- Single ascending dose of X842, Multiple ascending dose of X842, Food Effect
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Healthy Volunteer
A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
In Part 1, the primary objective is to investigate the effect of multiple doses of itraconazole, an inhibitor of CYP3A4, on the pharmacokinetic (PK) profile of a single dose of ASTX660.
- Trial name
- NCT04411030
- Testing
- ASTX660, Midazolam, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Astex Pharmaceuticals, Inc.
Venous Thromboembolism, Embolism and Thrombosis
Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.
- Conditions
- Venous Thromboembolism, Embolism and Thrombosis, Hip Fractures
- Trial name
- NCT00119457
- Testing
- TTP889
- Where
- 21 sites in Czechia, Denmark and 2 more
- Volunteers
- 300 people
- Sponsor
- vTv Therapeutics
Biliary Tract Cancer
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
To evaluate the preliminary efficacy of KA2507 (an orally active potent and selective HDAC6 inhibitor) in patients with advanced biliary tract cancer (BTC) previously treated with standard of care chemotherapy.
- Trial name
- NCT04186156
- Testing
- KA2507
- Where
- United Kingdom
- Sponsor
- Karus Therapeutics Limited
Type 2 Diabetes Mellitus in Obese, Obesity
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes
- Trial name
- NCT05409027
- Testing
- SPI-62, Cortisone-d8
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sparrow Pharmaceuticals
Tachycardia
INTRINSIC RV - Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs
INTRINSIC RV is a two-armed randomized trial that will compare the effects of innovative dual-chamber pacing with AV Search Hysteresis to standard VVI among ICD patients.
- Trial name
- NCT00148967
- Testing
- Implantable Cardioverter Defibrillator
- Volunteers
- 1,535 people
- Sponsor
- Boston Scientific Corporation